Syncytiotrophoblast extracellular vesicles contain functional kynurenine metabolising enzymes: potential implications for preeclampsia - Logenthiran, Prassana; Awoyemi, Toluwalase; Wilbourne, Morganne; Yu, Zhanru; Kessler, Benedikt; Escudero, Carlos; Zhang, Wei; Cerdeira, Sofia; Vatish, Manu (medRxiv, 2024)
Background Placentae of women with preeclampsia (PE) exhibit reduced levels of kynurenine (Kyn), a biological compound derived from tryptophan metabolism with antioxidant, vasorelaxant, and hypotensive properties. Little is known regarding functional levels of the Kyn metabolizing enzymes (KYNME) in women with preeclampsia. Since high circulating levels of syncytiotrophoblast extracellular vesicles (STB-EVs) have been associated with preeclampsia onset, we aimed to study whether Kyn reduction in preeclampsia may be attributed to increased degradation by KYNME present in STB-EVs.Methods We conducted a study that included women with normal (n=9) and early-onset preeclamptic (EOPE) pregnancies (n=9). From them, STB-EVs were isolated by dual-lobe placental perfusions from normal (n=3) and EOPE (n=3). KYNME were identified using placental immunohistochemistry and western blot in placental and STB-EV extractions. Serum Kyn levels were measured using gas chromatography mass spectrometry.Results Cargo of STB-EVs consist of functional KYNME, which break down Kyn in a dose and time-dependent manner. No significant differences in the content of Kyn metabolizing enzymes were found in STB-EVs between normal and EOPE pregnancies. However, decreased serum levels of Kyn were found in women with EOPE relative to normal pregnancies.Conclusion STB-EVs carry functional KYNME and may regulate the levels of circulating Kyn during normal pregnancy and preeclampsia. Due to the dose effect of increased STB-EVs in EOPE, the functional KYNME content of said vesicles may contribute to reduced levels of Kyn. This finding opens a new avenue for investigating the potential benefits of KYNME inhibitors in conjunction with kynurenine replacement for managing preeclampsia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by internal contingency funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central Oxfordshire Research Ethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript(TMCS)Chlorotrimethylsilane(GCxGC-MS)Comprehensive two-dimensional gas chromatography(EOPE)Early-onset preeclampsia(EVs)Extracellular vesicles(GCMS)Gas Chromatography Mass Spectrometry(ISSHP)International Society for the Study of Hypertension in Pregnancy(Kynu)Kynureninase(Kyn)Kynurenine(KAT-III)Kynurenine aminotransferase III(KMO)Kynurenine monooxygenase(KYNME)Kynurenine metabolizing enzymes(m/lSTB-EVs)Medium/large syncytiotrophoblast extracellular vesicles(MSTFA)N-Methyl-N-trimethylsilyltrifluoroacetamide(NTA)Nanoparticle tracking analysis(NP)Normal pregnancy(PLAP)Placenta alkaline phosphatase(IDO)Placental indoleamine 2,3-dioxygenase(PE)Preeclampsia(sSTB-EVs)Small syncytiotrophoblast extracellular vesicles(STB)Syncytiotrophoblast(STB-EVs)Syncytiotrophoblast extracellular vesicles(Trp)Tryptophan